PACULit Daily Literature Update: Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial Quiz

Liam is a 5-year-old boy admitted to the pediatric intensive care unit (PICU) with severe pneumonia requiring mechanical ventilation. His medical history is unremarkable, and he has no known drug allergies. Currently, he is sedated with intravenous midazolam 0.1 mg/kg/hr. The clinical team is considering alternative sedation strategies to optimize recovery and minimize opioid use.

Based on the IsoCOMFORT trial findings, what is the most appropriate pharmacist recommendation regarding sedation management for Liam?

Emma is a 3-year-old girl receiving inhaled isoflurane sedation via the AnaConDa device for mechanical ventilation due to acute respiratory distress syndrome. She has been sedated for 7 days. The PICU pharmacist is reviewing her sedation plan and monitoring parameters.

What is the most important safety consideration the pharmacist should communicate to the clinical team regarding prolonged inhaled isoflurane use in this patient?

Noah, a 6-year-old child on mechanical ventilation, is being transitioned from intravenous midazolam to inhaled isoflurane sedation. The PICU pharmacist is tasked with educating the multidisciplinary team on the new sedation protocol and monitoring requirements.

Which key point should the pharmacist emphasize to ensure safe implementation of inhaled isoflurane sedation in the PICU?